Literature DB >> 2146796

Resistance to levamisole and cross-resistance between pyrantel and levamisole in Oesophagostomum quadrispinulatum and Oesophagostomum dentatum of pigs.

H Bjørn1, A Roepstorff, P J Waller, P Nansen.   

Abstract

Two strains of Oesophagostomum spp., consisting of both O. quadrispinulatum and O. dentatum, were subjected to a controlled in vivo assay for resistance to levamisole and pyrantel by comparison with susceptible isolates. One strain (LEM) was recently isolated from a commercial herd, where sows showed high numbers of strongyle eggs in faeces within 2 weeks of farrowing and following treatment with levamisole at the manufacturer's recommended dose rate 1 week before farrowing. Levamisole had been used as the sole anthelmintic for treatment for at least 7 years on this farm. Treatment with pyrantel in this herd also indicated cross-resistance to this drug. A mixed population of O. quadrispinulatum and O. dentatum of this strain was subjected to controlled in vivo assays. Faecal egg count reduction (FECR) was found to be -573.3% (P greater than 0.05) and worm count reductions (WCR) of O. quadrispinulatum and O. dentatum were estimated as 44.5% (P greater than 0.05) and 96.4% (P less than 0.001), respectively. Treatment with pyrantel showed that cross-resistance existed to this drug, with FECR of 10.4% (P greater than 0.05) and WCR of 64.5% (P greater than 0.05) and 90.7% (P less than 0.05) for O. quadrispinulatum and O. dentatum, respectively. Another strain (VJ) was isolated from another commercial pig herd, which was dosed with pyrantel citrate four times a year for at least 8 years. This strain showed resistance to pyrantel, with FECR of 43.8% (P greater than 0.05) and WCR of 65.9% (P greater than 0.05) and 49.4% (P greater than 0.05) for O. quadrispinulatum and O. dentatum, respectively. However, both species were susceptible to levamisole. Our results suggested that selection with levamisole gave rise to levamisole resistance and automatically conferred resistance to pyrantel, whereas selection with pyrantel only resulted in resistance to this drug alone. These findings are discussed in relation to the location of the two species of Oesophagostomum in the large intestine of pigs and the mode of action of this class of anthelmintics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146796     DOI: 10.1016/0304-4017(90)90022-4

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  6 in total

1.  Microfluidics-enabled method to identify modes of Caenorhabditis elegans paralysis in four anthelmintics.

Authors:  Roy Lycke; Archana Parashar; Santosh Pandey
Journal:  Biomicrofluidics       Date:  2013-11-06       Impact factor: 2.800

2.  Efficacy of levamisole and ivermectin in the control of bovine parasitic gastroenteritis in the sub-humid savanna zone of southeastern Nigeria.

Authors:  I K Idika; E A Okonkwo; D N Onah; I O Ezeh; C N Iheagwam; C O Nwosu
Journal:  Parasitol Res       Date:  2012-07-04       Impact factor: 2.289

3.  Benzimidazole resistance in cyathostomin populations on horse farms in western Anatolia, Turkey.

Authors:  V Y Cirak; E Güleğen; C Bauer
Journal:  Parasitol Res       Date:  2004-06-18       Impact factor: 2.289

4.  The in vitro motility response to various anthelmintics of third-stage larvae of Oesophagostomum spp. from pigs.

Authors:  M Várady; J Corba; G Hrcková
Journal:  Vet Res Commun       Date:  1998-07       Impact factor: 2.459

5.  Management practices related to the control of gastrointestinal parasites on Swedish pig farms.

Authors:  Emelie Pettersson; Marie Sjölund; Torun Wallgren; Eva Osterman Lind; Johan Höglund; Per Wallgren
Journal:  Porcine Health Manag       Date:  2021-01-20

6.  Effective drug combination for Caenorhabditis elegans nematodes discovered by output-driven feedback system control technique.

Authors:  Xianting Ding; Zach Njus; Taejoon Kong; Wenqiong Su; Chih-Ming Ho; Santosh Pandey
Journal:  Sci Adv       Date:  2017-10-04       Impact factor: 14.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.